The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Lyell Immunopharma Inc shares valued at $19,958 were purchased by BRAWLEY OTIS W on Mar 31 ’25. At $0.56 per share, BRAWLEY OTIS W acquired 35,640 shares. The insider’s holdings grew to 35,640 shares worth approximately $0.34 million following the completion of this transaction.
Also, Ramachandra Sumant purchased 200,000 shares, netting a total of over 115,220 in proceeds. Following the buying of shares at $0.58 each, the insider now holds 200,000 shares.
Before that, Klausner Richard had added 158,000 shares to its account. In a trade valued at $94,942, the Director bought Lyell Immunopharma Inc shares for $0.60 each. Upon closing the transaction, the insider’s holdings increased to 158,000 shares, worth approximately $8.08 million.
As published in a research note from BofA Securities on October 30, 2024, Lyell Immunopharma Inc [LYEL] has been rated down from a Buy to an Underperform and the price target has been revised to $1 from $6. Analysts at H.C. Wainwright downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in late June. As of August 28, 2023, JP Morgan has decreased its “an Overweight” rating to a “Neutral” for LYEL. Earlier on November 14, 2022, Morgan Stanley downgraded its rating. Their new recommendation was “an Equal-weight” for LYEL stock which previously was a “an Overweight”.
Analyzing LYEL Stock Performance
On last trading session,, Lyell Immunopharma Inc [NASDAQ: LYEL] plunged -1.24% to $9.58. The stock’s lowest price that day was $9.455, but it reached a high of $10.45 in the same session. During the last five days, there has been a surge of approximately 1.81%. Over the course of the year, Lyell Immunopharma Inc shares have dropped approximately -25.16%. Shares of the company reached a 52-week high of $15.62 on 03/07/25 and a 52-week low of $7.65 on 06/02/25.
Support And Resistance Levels for Lyell Immunopharma Inc (LYEL)
According to the 24-hour chart, there is a support level at 9.21, which, if violated, would cause prices to drop to 8.83. In the upper region, resistance lies at 10.20. The next price resistance is at 10.82. RSI (Relative Strength Index) is 49.45 on the 14-day chart, showing neutral technical sentiment.
Is Lyell Immunopharma Inc subject to short interest?
Stocks of Lyell Immunopharma Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.25 million shares to 0.53 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 0.28 million shares. A jump of 46.71% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 16.43 of the overall float, the days-to-cover ratio (short ratio) jumped to 16.43.
Which companies own the most shares of Lyell Immunopharma Inc (LYEL)?
In terms of Lyell Immunopharma Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, down nearly -27.84% from the previous closing price of $9.70. Analysts anticipate Lyell Immunopharma Inc stock to reach 12 by 2025, with the lowest price target being 1. In spite of this, 3 analysts ranked Lyell Immunopharma Inc stock as Hold at the end of 2025. On November 11, 2022, Goldman assigned a price target of “a Neutral” to the stock and downgraded coverage with a $7.
